The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for ...
WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful ...
Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...
Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. Organizations regularly use non-disclosure agreements (NDAs) to ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Revive Therapeutics (RVVTF) announced an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent ...
A CDA or NDA assures the parties will protect any shared confidential information against unauthorized use or disclosure. A CDA or NDA is generally limited to a specific period of time. In the case of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback